Immune cells take on childhood cancer in early trial
NCT ID NCT02573896
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether giving children with relapsed neuroblastoma their own expanded natural killer (NK) cells along with the drug dinutuximab is safe and feasible. Some children may also receive lenalidomide. The study involves 13 participants aged up to 30 years and aims to find the best dose of NK cells while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Natural killer (NK) cells, dinutuximab, and lenalidomide
What this could lead to
If successful, this could point toward a new treatment option for children with hard-to-treat neuroblastoma that has come back.
What could go wrong
This is a very early phase 1 trial with only 13 participants, so it is mainly testing safety and dosing. It may not lead to a proven treatment, and side effects could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
Atlanta, Georgia, 30322, United States
-
C.S Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027-0700, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318, United States
-
Childrens Hospital Boston, Dana-Farber Cancer Institute.
Boston, Massachusetts, 02115, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
-
Cook Children's Healthcare System
Fort Worth, Texas, 76104, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94115, United States
-
University of Chicago Comer Children's Hospital
Chicago, Illinois, 60637, United States